Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × parsaclisib × Breast × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2 Dermatologic 1 Breast 1

Conditions

Triple Negative Breast Neoplasms 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 375 Trastuzumab 362 Paclitaxel 333 Docetaxel 283 Capecitabine 249 Letrozole 232 Carboplatin 226 Doxorubicin 192 Tamoxifen 168 Fulvestrant 161 Radiotherapy 159 Epirubicin 151 Anastrozole 144 pembrolizumab 131 Surveys and Questionnaires 130 Exercise 123 Vinorelbine 121 pertuzumab 119 Magnetic Resonance Spectroscopy 114 palbociclib 113 exemestane 113 Bevacizumab 110 Blood Specimen Collection 103 Albumin-Bound Paclitaxel 96 Drug Therapy 91 Gemcitabine 89 130-nm albumin-bound paclitaxel 87 eribulin 81 Biopsy 81 pyrotinib 78

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04142554 2020-11-03

LCCC1820

UNC Lineberger Comprehensive Cancer Center

Phase 1 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡